Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

February 1, 2017
Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mike Ward, Informa Pharma Intelligence insight global director of content, how his company’s approach has potential to double brain cancer survival.
Previous Article
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?
Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical ...

Next Video
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the t...